Stockscreener 앱 받기
0.9789
1.92%
0.0184
시간 외 거래:
.98
0.0011
+0.11%
전일 마감가:
$0.9605
열려 있는:
$0.96
하루 거래량:
632.87K
Relative Volume:
0.50
시가총액:
$105.34M
수익:
-
순이익/손실:
$-25.30M
주가수익비율:
-3.4836
EPS:
-0.281
순현금흐름:
$-18.79M
1주 성능:
+1.81%
1개월 성능:
-2.11%
6개월 성능:
-28.02%
1년 성능:
+57.76%
1일 변동 폭
$0.9348
$0.9999
1주일 범위
$0.9348
$1.04
52주 변동 폭
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9789 | 103.36M | 0 | -25.30M | -18.79M | -0.281 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 개시 | Lake Street | Buy |
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Biotech® to Host Conference Call to Discuss Second Qu - GuruFocus
Oncolytics Biotech Showcases Pelareorep as Immune-Priming Backbone With New AACR 2026 Data - TipRanks
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - marketscreener.com
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - GlobeNewswire Inc.
Stocks in play: Oncolytics Biotech Inc - Barchart
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
Oncolytics (ONCY) Presents Promising Cancer Research at AACR 202 - GuruFocus
Oncolytics Highlights New Pelareorep Data in Cancer Immunotherapy - TipRanks
Oncolytics Biotech (Nasdaq: ONCY) showcases new pelareorep immune-priming data at AACR 2026 - Stock Titan
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 - The Spec
Oncolytics Biotech Inc. (ONCY) Competitors - Meyka
Is It Time To Reconsider Oncolytics Biotech (ONCY) After A Huge DCF Valuation Gap? - simplywall.st
Growth Report: What is Oncolytics Biotech Incs market position2026 Growth vs Value & Fast Entry Momentum Alerts - baoquankhu1.vn
Insider Buying: James Parsons Acquires Additional Shares of Onco - GuruFocus
Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) Director Purchases 10,000 Shares of Stock - MarketBeat
Insider Buying: James Parsons Acquires Additional Shares of Oncolytics Biotech Inc (ONCY) - GuruFocus
Oncolytics Biotech (ONCY) director adds 10,000 common shares - Stock Titan
Oncolytics Biotech (ONCY) CEO buys 5,050 common shares at $0.96 - Stock Titan
ONCY Technical Analysis | Trend, Signals & Chart Patterns | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY SEC FilingsOncolytics Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
What is Oncolytics Biotech Incs 5 year growth outlookProduct Launch & Verified Swing Trading Watchlists - baoquankhu1.vn
How Oncolytics Biotech Inc. stock compares to market leadersProfit Target & Step-by-Step Swing Trade Plans - Naître et grandir
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types - marketscreener.com
Oncolytics Biotech Advances Pelareorep Into New Phase 2 Colorectal Cancer Study - TipRanks
Cancer Treatment Breakthroughs Stack Up as Clinical Pipelines Advance - Baystreet.ca
Earnings Report: Is Oncolytics Biotech Inc undervalued by DCF analysisJuly 2025 Drop Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion - Cantech Letter
Oncolytics Biotech Launches Randomized Phase 2 REO-033 Trial for Pelareorep in RAS-Mutant MSS Metastatic Colorectal Cancer — With FDA Fast Track Behind It - Oncodaily
Oncolytics launches phase 2 colorectal cancer study REO 033 By Investing.com - Investing.com Canada
Oncolytics launches phase 2 colorectal cancer study REO 033 - Investing.com
Oncolytics Biotech Launches Phase 2 Colorectal Cancer Trial - TipRanks
Oncolytics Biotech Launches Randomized Colorectal Cancer Study - Bitget
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech (NASDAQ: ONCY) launches Phase 2 pelareorep colorectal cancer study - Stock Titan
Oncolytics Biotech Inc initiates phase 2 study for metastatic colorectal cancer - marketscreener.com
Oncolytics (ONCY) Initiates Phase 2 Trial for Metastatic Colorec - GuruFocus
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study - The Manila Times
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Enrollment Milestone - simplywall.st
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Milestone - Sahm
Oncolytics Biotech (ONCY) Expected to Announce Earnings on Friday - MarketBeat
Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial - TradingView
Lake Street Sticks to Their Buy Rating for Oncolytics Biotech (ONCY) - The Globe and Mail
Oncolytics Biotech gains as enrollments for GIT cancer trial conclude - MSN
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 - Cantech Letter
Oncolytics to wind down GOBLET study, focus on U.S. registration - Investing.com India
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge - The Malaysian Reserve
Oncolytics Biotech (ONCY) Valuation Check After Recent Share Price Momentum And Conflicting Signals - Sahm
Death Cross: Will Oncolytics Biotech Inc outperform the market in YEARJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
Oncolytics Biotech (ONCY) Ends Enrollment in GOBLET Study to Foc - GuruFocus
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):